{"id":"W2576914903","doi":"10.1182/blood.v120.21.1637.1637","title":"Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Rituximab; Medicine; Tolerability; Fludarabine; Cyclophosphamide; Internal medicine; Population; Phases of clinical research; Pharmacokinetics; Oncology; Gastroenterology; Adverse effect; Pharmacology; Clinical trial; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005025526,0.0002714276,0.0008368664,0.0002361889,0.00006481272,0.00001635055,0.0001079206,0.00008227317,0.00000711454],"category_scores_gemma":[0.0001247209,0.0002117476,0.00002888446,0.0003465645,0.0002067252,0.0001385993,0.00009341056,0.0001843564,0.000001052978],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000473315,"about_ca_system_score_gemma":0.0006539923,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004846729,"about_ca_topic_score_gemma":0.0001523434,"domain_scores_codex":[0.9978371,0.00006980995,0.0005753711,0.0003785183,0.0006226716,0.0005165482],"domain_scores_gemma":[0.9985322,0.0003088342,0.0002098363,0.0003339472,0.0003661705,0.0002490263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2928368,0.2985262,0.3463905,0.003348183,0.001560502,0.0006509043,0.02542991,0.00007926888,0.004995732,0.00005468121,0.0001776167,0.02594974],"study_design_scores_gemma":[0.8596461,0.0314304,0.07920543,0.0005312338,0.0008517781,0.0003036492,0.0007126994,0.001600365,0.02516281,0.000009589857,0.000167897,0.0003780015],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9949874,0.0002447458,0.000152056,0.00006530071,0.00004197629,0.004129734,0.0002329179,0.00001735658,0.0001285229],"genre_scores_gemma":[0.9979142,0.0000566245,0.00167443,0.00004307939,0.00004110131,0.000102214,0.00009775062,0.00004735948,0.00002326623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5668093,"threshold_uncertainty_score":0.8634815,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01674751559810482,"score_gpt":0.3080953956362656,"score_spread":0.2913478800381608,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}